My current research concentrates on the study of signal transduction pathways involved in prostate cancer development and progression. This includes studies on the EGFR family of receptor tyrosine kinases, leading to the PI3K/Akt pathway and finally to the mTOR signaling pathway. In particular, I investigate the interaction of these pathways with the androgen receptor.
My research involves identification of significant therapeutic targets, as well as studying the effects of inhibitors of those targets both in vitro as well as in animal models. I am currently funded to study drug combinations that target parallel signaling pathways and in combination, appear to be highly effective in inhibiting the progression of prostate cancer.
M.Sc., Jadavpur University, Calcutta, India 1988
Ph.D., Rensselaer Polytechnic Institute, Troy NY 1994
B.Sc., Jadavpur University, Calcutta, India 1986
University of Texas Health Science Center, San Antonio TX 1994-2000
American Association for Cancer Research
American Association for the Advancement of Science
American Urological Association
The Society for Basic Urologic Research
Select Recent Publications
D’Abronzo LS, Bose S, Crapuchettes ME, Beggs RE, Vinall RL, Tepper CG, Siddiqui S, Mudryj M, Melgoza FU, Durbin-Johnson BP, deVere White RW, Ghosh PM. The Androgen Receptor is a negative regulator of eIF4E Phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer. Oncogene. 2017.
D'Abronzo LS, Pan CX, Ghosh PM. Evaluation of protein levels of the receptor tyrosine kinase ErbB3 in serum. in Urothelial Carcinoma: Methods and Protocols. Eds: Schulz WA, Hoffmann M, Niegisch G. Methods in Molecular Biology, Springer Science + Business Media, LLC, New York, NY. 2017.
Shih TC, Liu R, Fung G, Bharadwaj G, Ghosh PM, Lam K. A Novel Galectin-1 Inhibitor Discovered through One-Bead-Two-Compounds Library Potentiates the Anti-tumor Effects of Paclitaxel in vivo. Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0690.2016. [Epub ahead of print]
Chow H, Ghosh PM, deVere White RW, Evans CP, Dall’Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 Jun 15;122(12):1897-904.
Vinall RL, Tepper CG, Ripoll AZ, Gandour-Edwards RF, Durbin-Johnson BP, Yap SA, Ghosh PM, deVere White RW. Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapy. 2016. Genes & Cancer, Vol. 7 (3-4): 86-97.
Kiss Z, Ghosh PM. Circadian rhythmicity and the influence of 'clock' genes on prostate cancer. Endocrine-related cancer. 2016 Nov;23(11):T123-T134.
Pan, CX, Zhang, H, Tepper, CG, Lin, TY, Davis, RR, Keck, J, Ghosh, PM, Gill, P, Airhart, S, Bult, C, Gandara, DR, Liu, E, de Vere White, RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PloS one. 2016;10(8): e0134346.
Lombard, AP, Mooso, BA, Libertini, SJ, Lim, RM, Nakagawa, RM, Vidallo, KD, Costanzo, NC, Ghosh, PM, Mudryj, M. miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. Mol Carcinog. 2016; 55(5): 757-67.
Savoy, R.M., Chen, L., Siddiqui, S., Melgoza, F.U., Durbin-Johnson, B., Drake, C., Jathal, M.K., Bose, S., Steele, T.M., Mooso, B.A., D’Abronzo, L.S., Fry, W.H., Carraway, K.L. III, Mudryj, M. and Ghosh, P.M. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear Filamin A in prostate cancer. Endocrine-related Cancer. 2015. Mar 10. pii: ERC-15-0021 (PMID: 25759396).
D'Abronzo LS, Ghosh PM: Medical Treatment of Urological Malignancies (MTUM). The AKT/PI3K/PTEN pathway as a driver and therapeutic target in castration resistant prostate cancer. European Association for Urology (EAU) - International Consultation on Urologic Disease (ICUD) Consultation. 2015; p.325-336.
Savoy RM, Ghosh PM. The changing roles of steroid nuclear receptors with prostate cancer progression. Endocr Relat Cancer. 2013 Jul 4;20(4):C9-11